NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 318)
Posted On: 04/25/2018 7:45:59 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Definitive License Agreement with GP Holdings LLC.
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has entered a definitive technology licensing agreement with California cannabis beverage manufacturer GP Holdings LLC. Per the agreement, the company will provide its patented DehydraTECH™ technology to enable next-generation performance in high absorption, fast acting cannabis infused beverages to be developed and sold in California. The agreement grants GP five-year semi-exclusive rights to use Lexaria’s DehydraTECH™ technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on the products sold. In addition, GP has also acquired matching rights to develop topical skin products using the technology. “This is another long-term strategic relationship that will give consumers the faster acting and highly potent products they deserve, and class leading flavor profiles for the beverage segment in particular,” Lexaria CEO Chris Bunka stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has entered a definitive technology licensing agreement with California cannabis beverage manufacturer GP Holdings LLC. Per the agreement, the company will provide its patented DehydraTECH™ technology to enable next-generation performance in high absorption, fast acting cannabis infused beverages to be developed and sold in California. The agreement grants GP five-year semi-exclusive rights to use Lexaria’s DehydraTECH™ technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on the products sold. In addition, GP has also acquired matching rights to develop topical skin products using the technology. “This is another long-term strategic relationship that will give consumers the faster acting and highly potent products they deserve, and class leading flavor profiles for the beverage segment in particular,” Lexaria CEO Chris Bunka stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼